Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01039792 · ClinicalTrials.gov registry record · Phase 2
Trial of Methyl B12 on Behavioral and Metabolic Measures in Children With Autism
A Phase 2 study of Autistic Disorder, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 2
- Development phase
- 57
- Enrollment target
- 1
- Study location
NCT01039792 is a Phase 2 study of Autistic Disorder that has completed, run by University of California, San Francisco. The registered enrollment target is 57 participants, below the 112-participant average among 27 other Autistic Disorder trials with a reported enrollment target (49% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01039792, a Phase 2 study of Autistic Disorder, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 57 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether the supplement Methyl B12 is effective in treating some of the symptoms of Autism.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DRUG Methyl B12
Study Locations (1)
California
- UCSF - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2010-01 |
| Est. Completion | 2013-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01039792
The ClinicalTrials.gov registry entry for NCT01039792 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 112-participant average among 27 other Autistic Disorder trials with a reported enrollment target (49% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Autistic Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01039792 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01039792 about?
NCT01039792 is a clinical study titled "Trial of Methyl B12 on Behavioral and Metabolic Measures in Children With Autism". The purpose of this study is to determine whether the supplement Methyl B12 is effective in treating some of the symptoms of Autism.
What is the current status of trial NCT01039792?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2010-01. Estimated completion is 2013-11.
What conditions does trial NCT01039792 study?
This clinical trial studies the following conditions: Autistic Disorder.
What interventions are being tested in trial NCT01039792?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Methyl B12 (DRUG).
Who is sponsoring clinical trial NCT01039792?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01039792 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autistic Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sulforaphane in a New Jersey (NJ) Population of Individuals With Autism
ACTIVE NOT RECRUITING · Phase 2
-
Citalopram for Children With Autism and Repetitive Behavior (STAART Study 1)
COMPLETED · Phase 2
-
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
COMPLETED · Phase 2
-
A Study of Oral N-Acetylcysteine in Children With Autism Spectrum Disorders
COMPLETED · Phase 2
-
Donepezil HCl & Cognitive Deficits in Autism
COMPLETED · Phase 2
-
COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.